MyFinsight
Home
Blog
About
Contact
Proceeds from exercise of
warrants, net of issuance...
$16,217K
Net cash provided by
(used in) financing...
$16,217K
Net decrease in cash
and cash...
-$11,694K
Canceled cashflow
$16,217K
Non-cash interest
expense related to the...
$13,894K
Deferred revenue
$9,054K
Accounts receivable
-$7,838K
Accounts payable
$3,338K
Stock-based compensation
expense
$2,502K
Inventories
-$915K
Amortization of debt issuance
costs and discounts
$589K
Depreciation expense
$27K
Net cash used in
operating activities
-$27,722K
Canceled cashflow
$38,157K
Net cash used in
investing activities
-$189K
Net loss
-$25,196K
Non-cash royalty revenue
$18,481K
Prepaids and other assets
$17,338K
Other accrued
liabilities
-$4,864K
Purchase of property and
equipment
$189K
Back
Back
Cash Flow
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)
source: myfinsight.com